Effect of HIPEC After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-70
SponsorThe First Hospital of Jilin University
About this trial
The study focuses on patients with locally advanced gastric adenocarcinoma (cT3N+M0 and cT4aN+/-M0), assessing the feasibility, surgical safety, and oncological benefit of prophylactic HIPEC treatment following laparoscopic D2 radical surgery.
Eligibility criteria
Qualifiers
Age >18 and ≤70 years;
Male or nonpregnant female;
Gastric adenocarcinoma cT3N+M0 and cT4aN+/-M0 (according to the 8th edition of the AJCC TNM staging system);
No distant metastasis, suitable for D2 lymph node dissection;
Disqualifiers
Other cancers within the past 5 years;
Distant metastasis (M1) found during surgery;
ASA (American Society of Anesthesiologists) classification ≥IV and/or ECOG performance status >2;
Severe liver, kidney, cardiac, pulmonary, or coagulation dysfunction, or severe underlying diseases that make the patient unable to tolerate surgery;
Trial design
Treatments tested in this trial
- cisplatin oxaliplatin tegafur
Treatment groups
302 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov